FOR IMMEDIATE RELEASE
CONSHOHOCKEN, PA, COLUMBIA, MD; – Feb 9, 2006 – Fast Track Systems, Inc., a leading provider of clinical trial data and software designed to reduce the cost and improve productivity within clinical trial operations, today announced that CELSION CORPORATION (AMEX: CLN) has selected TrialSpace™ Grants Manager® and CROCAS PBT® for its global clinical trial planning and budgeting activities.
Dr. William Hahne, Celsion’s Vice President Clinical Development and Medical Affairs, commented, “Celsion plans to initiate a global multi-site Phase II/III clinical study to investigate the use of ThermoDox™, an encapsulation of doxorubicin in Celsion’s proprietary heat activated liposome, in combination with Radiofrequency Ablation to treat primary liver cancer. The Grants Manager and CROCAS date bases, which are representative of clinical costs for the global pharmaceutical industry, will be a useful tool in planning, budgeting and controlling the costs of this study”.
Fast Track Systems Vice President of Sales, Frank Cattie remarked, "As Celsion continues development of the company's first drug ThermoDox™ (doxorubicin encapsulated in the company's heat activated liposome) to treat cancer, our data and software will assist our new partner in proactively managing clinical trial costs. We are very pleased to be working with Celsion as they continue to pursue their research in cancer and to be adding them to our customer list of over 60 global clinical trial sponsor organizations."
About Fast Track Systems
Fast Track's products improve productivity, increase compliance, and reduce costs by solving problems associated with the operational aspects of clinical trial design and execution. TrialSpace Designer® ensures greater consistency and transparency in trial design by capturing protocol content as reusable data that can be utilized by other clinical systems and leveraged for related purposes. Grants Manager® and CROCAS® draw from over 25,000 finalized industry protocols, 240,000 negotiated investigator grants, and 4,000 CRO contracts to ensure subscribers understand the true cost and compliance consequences when negotiating clinical agreements. For further information on Fast Track Systems please visit our company website: www.Fast-Track.com.
About Celsion
Celsion Corporation, based in Columbia, Maryland, is a biotechnology company dedicated to the development and commercialization of heat activated treatment systems for cancer. Celsion has research, license or commercialization agreements with leading institutions such as the National Institute of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, please visit our website: www.celsion.com.